BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial

Opbroek, Thirza; Willems, Yves C.P.; Verhaegen, Frank; Ridder, Rogier de; Hoge, Chantal; Melenhorst, Jarno; Bakers, Frans C. H.; Grabsch, Heike; Buijsen, Jeroen; Limbergen, Evert J. Van; Canters, R.; Berbée, Maaike

doi:10.1016/j.ctro.2022.10.013

Cited by 1 publication

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, LIFE SRBs may be more appropriate for cervical or breast cancers, head and neck cancers or other tumors where liquid fiducials are used. An important benefit of the LIFE biomaterial is the similarities it has with liquid fiducials, which have been shown to have minimal migration and lessened scatter-induced image artefacts [ 14 , 15 , 16 , 17 , 44 ]. Both of these aspects are important to ensure viability as a dependable source for set up with scatter affecting image clarity and migration affecting relative positioning.…”

Section: Roadmap To Clinical Translationmentioning

confidence: 99%

Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination

Ainsworth,

Moreau,

Guthier

et al. 2023

Nanomaterials

View full text Add to dashboard Cite

Recent studies have highlighted the potential of smart radiotherapy biomaterials (SRBs) for combining radiotherapy and immunotherapy. These SRBs include smart fiducial markers and smart nanoparticles made with high atomic number materials that can provide requisite image contrast during radiotherapy, increase tumor immunogenicity, and provide sustained local delivery of immunotherapy. Here, we review the state-of-the-art in this area of research, the challenges and opportunities, with a focus on in situ vaccination to expand the role of radiotherapy in the treatment of both local and metastatic disease. A roadmap for clinical translation is outlined with a focus on specific cancers where such an approach is readily translatable or will have the highest impact. The potential of FLASH radiotherapy to synergize with SRBs is discussed including prospects for using SRBs in place of currently used inert radiotherapy biomaterials such as fiducial markers, or spacers. While the bulk of this review focuses on the last decade, in some cases, relevant foundational work extends as far back as the last two and half decades.

show abstract